Table 1.
Statistical comparison among baseline variables of subjects of group 1 and group 2.
| Group 1 | Group 2 | |
|---|---|---|
| (MMSE 16–23) | (MMSE 24–30) | |
| N = 43 | N = 37 | |
| Age, y | 73.5 ± 13 | 70.7 ± 11* |
| M/F | 29/14 | 24/13 |
| BMI (kg/m2) | 27 ± 8 | 26 ± 4 |
| NYHA class | 2.7 ± 0.5 | 2.2 ± 0.4* |
| Resting HR, bpm | 88 ± 7 | 76 ± 7* |
| Systolic BP, mmHg | 108 ± 19 | 107 ± 21 |
| Diastolic BP, mmHg | 82 ± 10 | 80 ± 14 |
| Echography | ||
| LVEF | 27.4 ± 7 | 34.9 ± 6* |
| LVDD | 63.1 ± 11 | 62.6 ± 8 |
| E/A | 1.4 ± 0.7 | 1.4 ± 0.8 |
| E deceleration time | 171 ± 23 | 180 ± 17 |
| Laboratory tests | ||
| NT proBNP, pg/mL | 302.7 ± 51 | 223.4 ± 34* |
| Creatinine, mg/dL | 1.9 ± 0.3 | 1.4 ± 0.5* |
| GFR, mL/min | 34.9 ± 9 | 50.1 ± 7* |
| Haemoglobin, g/dL | 10.4 ± 3 | 11.1 ± 4 |
| Comorbidities | ||
| Hypertension | 29 (67) | 24 (65) |
| Diabetes | 21 (48) | 12 (32)* |
| Dislipidemia | 17 (39) | 15 (40) |
| COPD | 16 (37) | 11 (30) |
| Atrial fibrillation | 15 (35) | 10 (27)* |
| Therapy | ||
| Beta-blockers | 36 (84) | 30 (81) |
| ACE-i/ARBs | 39 (91) | 36 (97) |
| Diuretics | 34 (79) | 27 (73) |
| Digoxin | 9 (21) | 6 (28) |
*Intergroup differences P < 0.05.
GFR: glomerular filtration rate.
LVDD: left ventricular diastolic diameter.
LVEF: left ventricular ejection fraction.